NOVO NORDISK A S
Novo Nordisk is a global healthcare company that discovers, develops, manufactures and markets pharmaceutical products and services for patients and the medical profession. Headquartered in Bagsværd, Denmark, it has two business segments: Obesity and Diabetes care, and Rare disease. Its portfolio includes GLP-1 receptor agonists such as Ozempic®, Wegovy® and Saxenda® for obesity and diabetes, modern and human insulins, and rare disease products mainly for growth hormone and haemophilia. Novo Nordisk also offers Wegovy® in injectable formats and as a pill. The company makes money by selling and distributing its pharmaceutical products through subsidiaries, distributors and independent agents across geographic markets. Its products are marketed in approximately 170 countries. Production includes active pharmaceutical ingredients, medicines and medical devices, with major production facilities in Denmark, the United States, France, China and Brazil.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $NVO in the last 30 days.
See all $NVO insider activity →Eli Lilly (LLY) and Regeneron (REGN) led gains in the VettaFi Weight Loss Drug & Treatment Index, which rose 3.28% in October. Lilly's Q3 revenue of $24.4B beat estimates, and it raised its 2026 forecast. Regeneron's revenue jumped 36%. AstraZeneca (AZN) and Roche also contributed to the index's gains, while CSPC Pharmaceutical Group and Structure Therapeutics fell.
Novo Nordisk (NVO) CEO Mike Doustdar stated that CVS Health's (CVS) planned breakup will not materially impact the company. He noted that Novo Nordisk will need to negotiate with two separate entities but expects continued demand for its weight-loss drugs. CVS plans to split into two publicly traded companies by mid-2028, separating its retail operations from its health insurance and pharmacy benefits businesses.
Novo Nordisk's CEO reported that the launch of the Wegovy pill has exceeded expectations, with record-breaking prescription volumes and market uptake. The company has expanded the pill's availability to nine markets and aims for 20 by the end of next year. Despite competition, Novo Nordisk maintains an 80% market share in the GLP-1 pill segment. The CEO highlighted the vast potential of the obesity market, with various patient needs catered by their portfolio.
Over the past 7 days, AlphAI's AI scored 57 news stories mentioning NVO (NOVO NORDISK A S). Coverage has skewed bullish: 47 bullish, 7 neutral, and 3 bearish.
Recent NVO coverage spans earnings, financial news and market movers.
Modest gain reflects market view of competitive landscape.
Management is signaling continuity of demand and access for Wegovy/Ozempic despite CVS structural changes.
Positive launch momentum may drive Novo Nordisk shares higher as demand outpaces expectations.
Beat on both EPS and sales is likely driving the immediate upside reaction and supporting near-term momentum in the GLP-1 obesity-drug complex.
Earnings beat plus raised guidance is supportive for NVO.
AlphAI scores every news story that mentions NVO with an AI model for sentiment and relevance, and aggregates insider trades from NOVO NORDISK A S's SEC EDGAR Form 4 filings. Figures refresh continuously.
Eli Lilly (LLY) and Regeneron (REGN) led gains in the VettaFi Weight Loss Drug & Treatment Index, which rose 3.28% in October. Lilly's Q3 revenue of $24.4B beat estimates, and it raised its 2026 forecast. Regeneron's revenue jumped 36%. AstraZeneca (AZN) and Roche also contributed to the index's gains, while CSPC Pharmaceutical Group and Structure Therapeutics fell.
Novo Nordisk (NVO) CEO Mike Doustdar stated that CVS Health's (CVS) planned breakup will not materially impact the company. He noted that Novo Nordisk will need to negotiate with two separate entities but expects continued demand for its weight-loss drugs. CVS plans to split into two publicly traded companies by mid-2028, separating its retail operations from its health insurance and pharmacy benefits businesses.
Novo Nordisk's CEO reported that the launch of the Wegovy pill has exceeded expectations, with record-breaking prescription volumes and market uptake. The company has expanded the pill's availability to nine markets and aims for 20 by the end of next year. Despite competition, Novo Nordisk maintains an 80% market share in the GLP-1 pill segment. The CEO highlighted the vast potential of the obesity market, with various patient needs catered by their portfolio.
Novo Nordisk (NVO) reported Q3 adjusted earnings of $0.87 per share, beating estimates of $0.73. Revenue reached $11.86B, exceeding expectations of $11.07B. The company's GLP-1 drugs drove the strong performance, causing the stock to rise 5% on the news.
Trump Media (DJT) shares fell 11% post-midterms. Tesla (TSLA) and SpaceX dropped 6-7%. Neocloud stocks declined 5-7%. Novo Nordisk (NVO) gained 6% on strong earnings. CVS (CVS) fell 2% on plans to split. McDonald's (MCD) rose 2% on mixed results. Duolingo (DUOL) surged 18% on strong Q3. Alight (ALIT) rose 22% on raised outlook. Avis (CAR) slid 2% on mixed Q3. AMD (AMD) was little changed after earnings beat. Toast (TOST) dropped 5% despite earnings beat.
NOVO NORDISK A S (NVO) furnished an SEC Form 6-K — earnings release. Novo Nordisk A/S Investor Relations Novo Alle 1 2880 Bagsværd Denmark Telephone: +45 4444 8888 www.novonordisk.com CVR Number: 24 25 67 90 Company announcement No 65 / 2026 Company Announcement Financial report for the period 1 January 2026 to 30 September 2026 4 November 2026 No
European shares rose slightly, led by Novo Nordisk's 6% gain after strong earnings and raised forecasts. U.S. midterm election results also influenced sentiment. Tech shares rebounded following AMD's strong results. Investors await eurozone CPI data for ECB rate hike clues.
Novo Nordisk (NYSE: NVO) reported Q3 EPS of $0.88, missing estimates by $3.74, and revenue of $12.01B, below the $73.4B consensus. The stock is down 14.96% over 3 months and 17.07% over 12 months. InvestingPro rates its financial health as 'great performance'.
Wednesday's earnings calendar features Arm, McDonald's, Novo Nordisk, Qualcomm, Uber, and AppLovin. Investors focus on semiconductor demand, consumer spending, healthcare growth, and digital advertising. Key metrics include EPS, forward guidance, and market trends. Last week, gold prices retreated, and forex markets saw volatility.
Novo Nordisk has repurchased 41.7 million shares since February 2026, totaling DKK 11.56 billion. The company plans to buy back shares worth up to DKK 15 billion within a year. As of November 2, 2026, it holds 55.75 million B shares as treasury shares. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B), and its ADRs are on the NYSE (NVO).
